137 related articles for article (PubMed ID: 35187646)
41. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
[TBL] [Abstract][Full Text] [Related]
42. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
44. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
45. Diagnosis and treatment of juvenile myelomonocytic leukemia.
Sakashita K; Matsuda K; Koike K
Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
[TBL] [Abstract][Full Text] [Related]
46. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.
Miles DK; Freedman MH; Stephens K; Pallavicini M; Sievers EL; Weaver M; Grunberger T; Thompson P; Shannon KM
Blood; 1996 Dec; 88(11):4314-20. PubMed ID: 8943868
[TBL] [Abstract][Full Text] [Related]
47. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
48. Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome.
Subirá D; Alhan C; Oelschlaegel U; Porwit A; Psarra K; Westers TM; Golbano N; Nilsson L; van de Loosdrecht AA; de Miguel D
Ann Hematol; 2021 Jul; 100(7):1711-1722. PubMed ID: 33423077
[TBL] [Abstract][Full Text] [Related]
49. Current Treatment of Juvenile Myelomonocytic Leukemia.
Mayerhofer C; Niemeyer CM; Flotho C
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300250
[TBL] [Abstract][Full Text] [Related]
50. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
[TBL] [Abstract][Full Text] [Related]
51. Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Cai Z; Zhang C; Kotzin JJ; Williams A; Henao-Mejia J; Kapur R
Blood Adv; 2020 Jul; 4(14):3246-3251. PubMed ID: 32697817
[TBL] [Abstract][Full Text] [Related]
52. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
53. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Platzbecker U; Wermke M; Radke J; Oelschlaegel U; Seltmann F; Kiani A; Klut IM; Knoth H; Röllig C; Schetelig J; Mohr B; Graehlert X; Ehninger G; Bornhäuser M; Thiede C
Leukemia; 2012 Mar; 26(3):381-9. PubMed ID: 21886171
[TBL] [Abstract][Full Text] [Related]
54. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
[TBL] [Abstract][Full Text] [Related]
55. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
[TBL] [Abstract][Full Text] [Related]
56. Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukemia: A study from Northern India.
Sharma M; Sachdeva MU; Varma N; Varma S; Marwaha RK
J Cancer Res Ther; 2016; 12(2):620-6. PubMed ID: 27461621
[TBL] [Abstract][Full Text] [Related]
57. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
58. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
[TBL] [Abstract][Full Text] [Related]
59. Human umbilical cord blood: immunophenotypic heterogeneity of CD34+ hematopoietic progenitor cells.
D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Zendoli F; Carotenuto M
Haematologica; 1996; 81(5):404-9. PubMed ID: 8952152
[TBL] [Abstract][Full Text] [Related]
60. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
